Isoform Switching as a Regulatory Mechanism of Glycolytic Reprogramming in Cancer
- 1Department of Medical Biochemistry, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania
- 2Department of Pharmaceutical Biochemistry and Clinical Laboratory, Faculty of Pharmacy, “Iuliu-Hațieganu” University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania
- 3Department of Inorganic Chemistry, Faculty of Pharmacy, “Iuliu-Hațieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
Abstract
Cancer-associated metabolic reprogramming is a dynamic process that supports tumor growth, adaptation, and therapeutic resistance. Among the post-transcriptional mechanisms contributing to this plasticity, alternative splicing has emerged as an important regulator of glycolytic metabolism by generating transcript and protein isoforms with distinct biochemical and regulatory properties. This review examines the molecular mechanisms linking alternative splicing to cancer glycolysis, with particular emphasis on pyruvate kinase M1/pyruvate kinase M2 (PKM1/PKM2) isoform regulation as the best-characterized, but context-dependent, model of splice-associated metabolic control rather than as a universal tumor-specific switch. Additional splice-dependent mechanisms affecting glycolysis-related enzymes, transporters, receptors, and regulatory proteins further illustrate that the metabolic impact of alternative splicing extends beyond PKM and may influence glucose uptake, glycolytic enzyme activity, pyruvate fate, and lactate metabolism. The review further highlights the regulatory roles of key RNA-binding proteins and splicing factors, together with upstream oncogenic signaling pathways, in establishing cancer-associated splicing programs. Hypoxia, glucose and energy stress, lactate-dependent protein lactylation, and oxidative stress can modify spliceosomal activity and splicing-factor function, whereas extracellular acidosis is better regarded as a potential modulatory input whose independent role in splice-site selection remains less firmly established. Functionally, splicing-driven glycolytic remodeling contributes to tumor growth, metabolic adaptation, invasion, metastasis, cancer stemness, and therapy resistance. Therapeutically, the splicing–glycolysis axis may be exploited through modulation of the splicing machinery, antisense oligonucleotide-mediated splice switching, isoform-directed strategies, and combined or synthetic-lethal approaches targeting splice-induced metabolic dependencies. Future studies integrating isoform-resolved transcriptomics with proteomics, metabolomics, spatial and single-cell approaches, and metabolic flux analysis will be essential for distinguishing functionally relevant splice variants from non-functional transcript diversity and for identifying clinically actionable metabolic vulnerabilities.
Related
- Oncogenic CLDN1 promotes thyroid cancer progression through TAp63-mediated glycolytic switching
- Multidimensional Roles of Deubiquitinases in Tumor Glycolytic Reprogramming
- A Hypertrophic Stimulus Drives Age-Dependent Transcript Isoform Switching With and Without Differential Gene Expression in Skeletal Muscle.
- HIF1A-AS2 Regulates Hypoxia-Driven HIF Isoform Switching in Human Endothelial Cells
- Hypoxia-Associated Glycolytic–Lipogenic Reprogramming and Impaired Antigen Presentation in SPP1+ Tumor-Associated Macrophages in Ovarian Cancer
BibTeX
@article{procopciuc2026isoform,
title = {{Isoform Switching as a Regulatory Mechanism of Glycolytic Reprogramming in Cancer}},
author = {Lucia Maria Procopciuc and Roxana Liana Lucaciu and Adriana Corina Hangan},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms272210242},
url = {https://www.mdpi.com/1422-0067/27/22/10242},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Isoform Switching as a Regulatory Mechanism of Glycolytic Reprogramming in Cancer
AU - Lucia Maria Procopciuc
AU - Roxana Liana Lucaciu
AU - Adriana Corina Hangan
PY - 2026
DA - 2026/11/15
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms272210242
UR - https://www.mdpi.com/1422-0067/27/22/10242
AB - Cancer-associated metabolic reprogramming is a dynamic process that supports tumor growth, adaptation, and therapeutic resistance. Among the post-transcriptional mechanisms contributing to this plasticity, alternative splicing has emerged as an important regulator of glycolytic metabolism by generating transcript and protein isoforms with distinct biochemical and regulatory properties. This review examines the molecular mechanisms linking alternative splicing to cancer glycolysis, with particular emphasis on pyruvate kinase M1/pyruvate kinase M2 (PKM1/PKM2) isoform regulation as the best-characterized, but context-dependent, model of splice-associated metabolic control rather than as a universal tumor-specific switch. Additional splice-dependent mechanisms affecting glycolysis-related enzymes, transporters, receptors, and regulatory proteins further illustrate that the metabolic impact of alternative splicing extends beyond PKM and may influence glucose uptake, glycolytic enzyme activity, pyruvate fate, and lactate metabolism. The review further highlights the regulatory roles of key RNA-binding proteins and splicing factors, together with upstream oncogenic signaling pathways, in establishing cancer-associated splicing programs. Hypoxia, glucose and energy stress, lactate-dependent protein lactylation, and oxidative stress can modify spliceosomal activity and splicing-factor function, whereas extracellular acidosis is better regarded as a potential modulatory input whose independent role in splice-site selection remains less firmly established. Functionally, splicing-driven glycolytic remodeling contributes to tumor growth, metabolic adaptation, invasion, metastasis, cancer stemness, and therapy resistance. Therapeutically, the splicing–glycolysis axis may be exploited through modulation of the splicing machinery, antisense oligonucleotide-mediated splice switching, isoform-directed strategies, and combined or synthetic-lethal approaches targeting splice-induced metabolic dependencies. Future studies integrating isoform-resolved transcriptomics with proteomics, metabolomics, spatial and single-cell approaches, and metabolic flux analysis will be essential for distinguishing functionally relevant splice variants from non-functional transcript diversity and for identifying clinically actionable metabolic vulnerabilities.
SN - 1422-0067
ER -